Breaking News Instant updates and real-time market news.

FCX

Freeport McMoRan

$15.33

0.36 (2.40%)

, ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

10:22
11/30/16
11/30
10:22
11/30/16
10:22

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 2. Arrowhead (ARWR) was downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Buy at Chardan, to Hold from Buy at Cantor, and to Market Perform from Outperform at William Blair. 3. W.R. Grace (GRA) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. 4. Abaxis (ABAX) downgraded to Neutral from Buy at Northcoast. 5. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing the stock's recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

FCX

Freeport McMoRan

$15.33

0.36 (2.40%)

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

GRA

W.R. Grace

$65.00

-2.01 (-3.00%)

ABAX

Abaxis

$52.21

0.28 (0.54%)

DLTH

Duluth Holdings

$35.00

-2.64 (-7.01%)

  • 30

    Nov

FCX Freeport McMoRan
$15.33

0.36 (2.40%)

11/14/16
MACQ
11/14/16
NO CHANGE
Target $13
MACQ
Outperform
Freeport McMoRan price target raised to $13 from $9 at Macquarie
Macquarie analyst Anthony Young raised Freeport's price target to $13 from $9 in conjunction with the Commodities' team increase in copper price forecast by 17% in 2017 to $2.43/lb and 16% in 2018 to $2.13/lb. The analyst likes Freeport's leverage to the price of copper and expects the company to ultimately reach an agreement with the Indonesia government on the company's permit to export. Young has an Outperform rating on Freeport shares.
11/30/16
BREN
11/30/16
DOWNGRADE
BREN
Sell
Freeport McMoRan downgraded to Sell from Hold at Berenberg
11/21/16
COWN
11/21/16
NO CHANGE
Target $20
COWN
Outperform
Freeport McMoRan price target raised to $20 from $15 at Cowen
Cowen analyst Anthony Rizzuto raised his price target on Freeport McMoRan to $20 from $15 as the company has regained its status as the "go-to" coper investment vehicle after the impressive action taken by management to right-size the balance sheet. Rizzuto reiterated his Outperform rating on Freeport McMoRan shares.
11/17/16
DBAB
11/17/16
DOWNGRADE
Target $12.5
DBAB
Hold
Freeport McMoRan downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Freeport McMoRan to Hold citing valuation following the recent rally in the shares. The analyst keeps a $12.50 price target for the stock.
ARWR Arrowhead
$4.39

-0.07 (-1.57%)

11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded on competitor withdrawal at Chardan
As noted earlier, Chardan upgraded Arbutus (ABUS) to Buy from Neutral. Analyst Gbola Amusa upgraded the stock after Arrowhead (ARWR) announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT. The analyst now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Amusa does not expect Arbutus' treatments to cause the same safety problems as those of Arrowhead. Amusa is upbeat on Arbutus' lead asset, ARB-1467. Target to $4 from $3.
11/30/16
WBLR
11/30/16
DOWNGRADE
WBLR
Market Perform
Arrowhead downgraded to Market Perform from Outperform at William Blair
11/30/16
CANT
11/30/16
DOWNGRADE
CANT
Hold
Arrowhead downgraded on elimination of program at Cantor
As noted earlier, Cantor downgraded Arrowhead to Hold from Buy. Analyst Elemer Piros downgraded the stock after the company announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT but pursuing its subcutaneously delivered candidates. The analyst says that the subcutaneously delivered candidates are in early stages of development and lack visibility. Target to $1 from $15.
11/30/16
11/30/16
DOWNGRADE
Target $2

Market Perform
Arrowhead downgraded at William Blair after clinical programs discontinued
As previously reported, William Blair analyst Katherine Xu downgraded Arrowhead to Market Perform from Outperform after the company announced that it would discontinue all of its current clinical-stage programs three weeks after the FDA placed lead asset ARC-520 for hepatitis B virus on clinical hold. The company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, though Xu estimates these programs are at least one to two years away from entering the clinic. Xu cut her price target on Arrowhead shares to $2 from $12.
GRA W.R. Grace
$65.00

-2.01 (-3.00%)

11/30/16
JEFF
11/30/16
DOWNGRADE
JEFF
Hold
W.R. Grace downgraded to Hold from Buy at Jefferies
11/30/16
11/30/16
DOWNGRADE
Target $70

Hold
W.R. Grace downgraded to Hold at Jefferies
As previously reported, Jefferies analyst Laurence Alexander downgraded W.R. Grace to Hold from Buy, noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. Alexander also sees medium-term demand risks for gasoline and said that Grace leans heavily on buybacks and M&A for its EPS growth, which could threatens the stock's multiple. The analyst lowered his price target on Grace shares to $70 from $80.
11/01/16
GHSC
11/01/16
UPGRADE
GHSC
Buy
W.R. Grace upgraded to Buy from Neutral at Seaport Global
09/13/16
GHSC
09/13/16
INITIATION
Target $81
GHSC
Neutral
W.R. Grace initiated with a Neutral at Seaport Global
Seaport Global analyst Michael Harrison initiated W.R. Grace with a Neutral and an $81 price target due to valuation. The analyst adds he views Grace a potential takeout target following the spin-out of its GCP construction and packaging business, and notes there has been brisk M&A activity in the chemicals and materials space recently.
ABAX Abaxis
$52.21

0.28 (0.54%)

11/30/16
NRCS
11/30/16
DOWNGRADE
NRCS
Neutral
Abaxis downgraded to Neutral from Buy at Northcoast
07/22/16
FLTL
07/22/16
DOWNGRADE
FLTL
Sell
Abaxis downgraded to Sell from Hold at Feltl
02/04/16
02/04/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at DA Davidson... Abaxis (ABAX) initiated with an Underperform at Credit Suisse... Aratana Therapeutics (PETX) initiated with an Outperform at Credit Suisse... Care.com (CRCM) initiated with an Equal Weight at Morgan Stanley... GCP Applied Technologies (GCP) initiated with a Buy at Jefferies... Heritage-Crystal Clean (HCCI) initiated with a Buy at Roth Capital... IDEXX (IDXX) initiated with an Outperform at Credit Suisse... Nexvet Biopharma (NVET) initiated with an Outperform at Credit Suisse... PetMed Express (PETS) initiated with an Underperform at Credit Suisse... Phibro Animal Health (PAHC) initiated with an Outperform at Credit Suisse... Pure Storage (PSTG) initiated with a Perform at Oppenheimer... SeaWorld (SEAS) initiated with a Neutral at Janney Capital... Seattle Genetics (SGEN) initiated with an Overweight at Barclays... VCA Inc. (WOOF) initiated with an Outperform at Credit Suisse... Verizon (VZ) initiated with a Neutral at DA Davidson... Zoetis (ZTS) initiated with an Outperform at Credit Suisse.
02/04/16
FBCO
02/04/16
INITIATION
Target $39
FBCO
Underperform
Abaxis initiated with an Underperform at Credit Suisse
Credit Suisse analyst Erin Wilson initiated Abaxis with an Unperform rating and $39 price target on shares. Wilson sees slowing growth, increasing competition, and reduced contributions from new distribution relationships pressuring earnings growth.
DLTH Duluth Holdings
$35.00

-2.64 (-7.01%)

11/30/16
BARD
11/30/16
DOWNGRADE
Target $39
BARD
Neutral
Duluth Holdings downgraded to Neutral at Baird
As reported previously, Baird analyst Jonathan Komp downgraded Duluth Holdings to Neutral from Outperform. The analyst cited its recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. Komp raised his price target to $39 from $36 on Duluth Holdings shares.
11/30/16
BARD
11/30/16
DOWNGRADE
BARD
Neutral
Duluth Holdings downgraded to Neutral from Outperform at Baird
09/23/16
BMOC
09/23/16
NO CHANGE
BMOC
Duluth Holdings weakness creates attractive entry point, says BMO Capital
After traveling with Duluth's management, BMO Capital analyst John Morris says the company can continue to accelerate its store expansions and the growth of its women's business. He remains upbeat on the company's long-term outlook, and he says that the weakness in the stock has created a buying opportunity.
09/08/16
BARD
09/08/16
NO CHANGE
Target $35
BARD
Outperform
Duluth Holdings removed from Focus Ideas List at Baird
Baird analyst Jonathan Komp removed Duluth from Baird's Focus List entirely due to the recent strong share performance. The analyst maintains his Outperform rating and $35 price target saying he remains confident in Duluth's near-term fundamentals.

TODAY'S FREE FLY STORIES

AIZ

Assurant

$94.03

-0.05 (-0.05%)

17:10
01/22/18
01/22
17:10
01/22/18
17:10
Syndicate
Breaking Syndicate news story on Assurant »

Assurant files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

FSLR

First Solar

$68.96

-1.07 (-1.53%)

17:08
01/22/18
01/22
17:08
01/22/18
17:08
Technical Analysis
Technical Take: First Solar spikes after tariff decision »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRO

Brown & Brown

$52.25

-0.25 (-0.48%)

17:05
01/22/18
01/22
17:05
01/22/18
17:05
Earnings
Brown & Brown reports Q4 EPS 47c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EAT

Brinker

$38.39

0.08 (0.21%)

, GS

Goldman Sachs

$261.52

5.4 (2.11%)

17:03
01/22/18
01/22
17:03
01/22/18
17:03
Hot Stocks
Brinker adds James Katzman To Board of Directors »

Brinker (EAT) announces…

EAT

Brinker

$38.39

0.08 (0.21%)

GS

Goldman Sachs

$261.52

5.4 (2.11%)

HSY

Hershey

$109.96

0.59 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

  • 01

    Feb

CCXI

ChemoCentryx

$8.31

-0.04 (-0.48%)

17:01
01/22/18
01/22
17:01
01/22/18
17:01
Hot Stocks
ChemoCentryx reports 'positive' survival results from CCX872 trial »

ChemoCentryx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TROW

T. Rowe Price

$117.40

0.05 (0.04%)

16:57
01/22/18
01/22
16:57
01/22/18
16:57
Hot Stocks
T. Rowe Price sees FY18 effective tax rate 24%-27% »

On December 22, 2017, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$75.83

0.23 (0.30%)

16:45
01/22/18
01/22
16:45
01/22/18
16:45
Hot Stocks
Natixis, NYSE enter licensing agreement »

Natixis Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$21.21

1.72 (8.83%)

16:43
01/22/18
01/22
16:43
01/22/18
16:43
Syndicate
Breaking Syndicate news story on Catalyst Biosciences »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$5.74

0.03 (0.53%)

16:40
01/22/18
01/22
16:40
01/22/18
16:40
Hot Stocks
Investors Real Estate completes sale of two additional medical office buildings »

IRET completed the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIC

Flushing Financial

$28.93

-0.1 (-0.34%)

16:39
01/22/18
01/22
16:39
01/22/18
16:39
Hot Stocks
Flushing Financial announces dividend plans for 2018 »

Flushing Financia, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

JMBA

Jamba

$9.14

-0.01 (-0.11%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Syndicate
Jamba 2.1M share Block Trade; price range $8.25-$8.40 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.65

0.1 (0.54%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Earnings
Fulton Financial reports Q4 EPS 19c, consensus 28c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36
Hot Stocks
Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study »

Amgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN

Amgen

$192.33

3.05 (1.61%)

16:34
01/22/18
01/22
16:34
01/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen: Aimovig met all…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

FL

Foot Locker

$50.37

0.16 (0.32%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
Foot Locker makes strategic investment in Carbon38 »

Foot Locker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPE

EP Energy

$2.48

0.17 (7.36%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
EP Energy sees FY18 $600M-$650M of oil and gas expenditures, »

Sees FY18 81…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$98.06

-0.98 (-0.99%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Darden names Dave George as COO »

Darden Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

, WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Rite Aid provides update on sale of assets to Walgreens Boots Alliance »

Rite Aid Corporation…

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$54.16

0.43 (0.80%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Earnings
Zions Bancorp reports Q4 adjusted EPS 80c, consensus 73c »

Harris H. Simmons,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
EP Energy reports preliminary FY17 production results of 82,300MBoe/d »

Preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

RMD

ResMed

$87.51

-1.17 (-1.32%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
Breaking Hot Stocks news story on ResMed »

ResMed up 8.5% to $95.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EMR

Emerson

$73.26

0.12 (0.16%)

16:29
01/22/18
01/22
16:29
01/22/18
16:29
Initiation
Emerson initiated  »

Emerson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.